Paul Walker, M.D., Ph.D., F.R.C.S.C

Director, President & Chief Executive Officer

Dr. Paul WalkerDr. Walker joined Spectral as President and CEO in April 2001. Previously, he held the position of COO of the Toronto General Hospital, and was Surgeon in Chief and Vice President of the Surgical Directorate of the University Hospital Network. Dr. Walker was an active Vascular Surgeon and the Director of the Intensive Care Program, and Professor of Medicine and Laboratory Medicine at the University of Toronto.

A pioneer in the area of endotoxin and its role in sepsis, and the co-inventor of the Endotoxin Activity Assay (EAA™), Dr. Walker is a frequent participant at leading sepsis and critical care conferences, has been a keynote speaker at symposiums focusing on the role of endotoxin in sepsis, and is the author of over 100 scientific publications. He received his M.D. from the University of Western Ontario, his Ph.D. from the Salgrenska University of Göteborg, Sweden, and is a graduate of the Advanced Management Program from Harvard School of Business.


Richard Wieland

Chief Financial Officer

Tony BusinskasMr. Wieland joined Spectral in February 2018 as Interim CFO. Previously he was EVP and CFO of Unilife Corporation, a medical device company working in the pre-filled syringe and infusion pump areas. Mr. Wieland is a senior financial executive with a diversified Life Science business background that has involved both line and staff experience and more than thirty five years of business experience in both public and private companies working with the Audit, Compensation and Governance committees of the Board.

Mr. Wieland has completed over twenty capital transactions raising over $830 million including two successful IPOs and eleven M&A transactions valuing $1.2 billion. Subsequent to several M&A transactions, he successfully managed the post-acquisition integration programs. Mr. Wieland served on the Board of a NASDAQ home healthcare company and is currently a Board Member of Voxello Inc., a medical device Company.


Debra M. Foster, B.Sc. (Human Biology)

Vice President, Clinical Development

Debra M. FosterMs. Foster brings more than 20 years of experience to the Spectral team. Starting her career as registered Nurse specializing in the adult critical care setting, Ms. Foster’s research experience began as a clinical research coordinator for the Medical Surgical Intensive Care Unit of Toronto General Hospital. This included being an active member of the Canadian Critical Care Trials group where she developed expertise in clinical trial design, operation and execution.

Ms. Foster is a former Certified Clinical Research Coordinator (CCRC) and has lectured to medical professionals on the topics of sepsis and clinical trials for sepsis internationally. Ms. Foster holds a Bachelor of Sciences degree in Human Biology from the University of Toronto.


Dr. Gualtiero Guadagni, Ph.D

Vice President, Sales and Marketing

Dr. Gualtiero GuadagniDr. Guadagni is responsible for the development and expansion of commercial opportunities for Toraymyxin and Spectral’s Endotoxin Activity Assay (EAA™) in Canada, the United States and Europe.

Dr. Guadagni has extensive experience in market development and sales of the EAA and Toraymyxin theranostic approach to the management of septic shock in regions outside of North America.

Prior to joining Spectral, Dr. Guadagni spent 10 years at ESTOR S.P.A where he was the company’s sales and marketing director, and scientific consultant for Toraymyxin. ESTOR is a Milano-based company specialized in the production, promotion and sale of advanced biomedical devices in the areas of dialysis, intensive care and hemodynamics.

As ESTOR’s sales and marketing director, Dr. Guadagni managed an 18-person sales and marketing  team that focussed on selling and marketing Dialysis products on the Italian Market, as well as intensive care product such as Toraymyxin,  EAA and proLUNG in Italy, Switzerland and Austria where the sales of EAA and Toraymyxin have grown annually.

As ESTOR’s scientific responsible, he coordinated a number of post-marketing clinical trials such as the “Euphas” trial (Early Use of Polymyxin B Hemoperfusion In Abdominal septic Shock). In 2010, he coordinated Euphas2 (, an international data registry for Toraymyxin and EAA use in critically ill patients with septic shock, in multiple countries worldwide.

Dr. Guadagni has a PhD in bioengineering and a master’s degree in mechanical engineering, both from Politecnico di Milano University in Italy.

Spectral Medical Inc. © 2014-2019

135 The West Mall , Unit 2 •  Toronto, Ontario  •  M9C 1C2  Canada

Tel: 1.416.626.3233  •  Toll Free: 1.888.426.4264  •  Fax: 1.416.626.7383